1 September 2024

Appendix 4C - Quarterly Cashflow Report

 

Melbourne, Australia; 28 July 2011 – Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today released its Appendix 4C – Quarterly Cash Flow Report for the period ended 30 June 2011.

The net cash burn for the year was $3.9m, resulting in a cash balance of $18.9m at 30 June 2011.

The total operating and investing cash outflow for the quarter was $1.2m and the total for the financial year to 30 June 2011 was $6.7m. This included costs for the recently completed Phase 2 clinical trial that demonstrated efficacy of VivaGel® as a treatment for bacterial vaginosis. Financing cash inflows of $3.6m resulted from the exercise of share options during the year. Receipts from customers included royalty, license and research income from the Company’s growing list of partners.

 

Download ASX Announcement: Appendix 4C - Quarterly Cashflow Report

This contains certain forward-looking statements.

Important Notice

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.